Acumen Pharmaceuticals, Inc. (ABOS)
ABOSNASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$0.2251
-0.0049 (-2.13%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $0.2252 -2.09%
- Market cap
- $16.29m
- P/E
- –
- EPS, last 4 quarters
- $-1.54
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.1911 to $3.60
- Average volume
- –
- Previous close
- $0.2300
Analysts
6 coveringUnderperform1 buy, 3 hold, 2 sell
Targets a year out average $1.00, +344.2% from here
Earnings
next estimate $-0.4700Next report
Dec 2025
+18.0%
Mar 2026
–
Jun 2026
-15.4%
Sep 2026
+18.6%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$25.20m | -$21.15m | -$32.56m | -$25.81m |
| Net income | -$25.14m | -$20.74m | -$32.72m | -$25.37m |
News
8 latest- Acumen Pharmaceuticals, Inc. Announces 90% Workforce Reduction and Terminates Loan Agreement with $23.3 million PayoffFintel · 6 days ago
- Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term InvestorsThe Motley Fool · Nov 4, 2026
- Acumen Shares Drop 89% After Sabirnetug Fails Phase 2 Alzheimer's Trial RTTNews · Oct 30, 2026
- Acumen Halts Sabirnetug Development After Phase 2 Trial Miss RTTNews · Oct 30, 2026
- Acumen Q3 Loss Narrows; Alzheimer's Trial Results Due November 2026 RTTNews · Oct 27, 2026
- Three Movers And A Catalyst: SGRY, XNCR, ORKA Gain As Acumen Nears ALTITUDE-AD Readout RTTNews · Oct 26, 2026
- Acumen Pharmaceuticals (ABOS) Q3 2026 Earnings Call TranscriptThe Motley Fool · Oct 26, 2026
- Acumen Pharmaceuticals Q3 Earnings Call HighlightsMarketBeat · Oct 26, 2026
The company
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble AOs for the treatment of AD. Acumen's scientific founders pioneered research on AOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer's disease pathology. Acumen's lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AOs, was evaluated in the Phase 2 ALTITUDE-AD clinical trial (NCT06335173) in early symptomatic Alzheimer's disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme's proprietary ENHANZE drug delivery technology.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- acumenpharm.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.